Brief: InspireMD Announces Inclusion Of Its CGuard Carotid Stent In Crest-2 Trial
28/02/2022 12:48
Feb 28 (Reuters) - InspireMD Inc NSPR.O :
* INSPIREMD ANNOUNCES THE INCLUSION OF ITS CGUARD CAROTID
STENT IN
CREST-2 TRIAL FOLLOWING FDA APPROVAL OF THE INVESTIGATIONAL
DEVICE EXEMPTION SUPPLEMENT APPLICATION
Source text for Eikon: ID:nGNXB5HKs
Further company coverage: NSPR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on InspireMD
See all newsInspireMD Inc reports results for the quarter ended June 30 - Earnings Summary
InspireMD Q2 revenue beats estimates on international demand
InspireMD Inc expected to post a loss of 20 cents a share - Earnings Preview
InspireMD Inc expected to post a loss of 20 cents a share - Earnings Preview
InspireMD Q1 revenue jumps 122%, beats estimates on product demand